The three companies will collaborate to
improve global access to advanced cancer testing and data,
broadening access to cutting-edge science
BOSTON and ROLLE, Switzerland, Oct. 18,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a category-defining software company and a global leader in
data-driven medicine today announced a collaboration with Memorial
Sloan Kettering Cancer Center (MSK), a top cancer
treatment and research institution, and AstraZeneca
(LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer
testing to a global scale. With this collaboration, the three
leading organizations will further their shared goal to advance
health equity on a global scale by providing inclusive access to
comprehensive cancer testing worldwide.
Cancer is the second leading cause of death worldwide. In 2020,
10 million deaths were attributed to cancer, 70 percent of which
occurred in low- and middle-income countries.1 While
there are multifaceted reasons for this disparity, a top
contributor is the lack of adequate testing, which can lead to
prevention, early detection, and advanced treatment. Through the
newly announced partnership, SOPHiA GENETICS, MSK, and AstraZeneca
will create a decentralized global network for cancer
testing, including underserved regions where access to testing
remains scarce.
The partnership will provide MSK's proprietary liquid biopsy and
solid tumor cancer tests – MSK-ACCESS® and MSK-IMPACT® – to
organizations via the decentralized,
technology-agnostic SOPHiA DDM™ Platform. This offering will be
rapidly deployed by SOPHiA GENETICS with support from AstraZeneca's
global footprint. Through SOPHiA GENETICS' cloud-based platform,
which provides highly accurate and reliable data and insights,
institutions around the world – and in traditionally
under-resourced and under-served areas – will have the power to
make data-driven decisions.
"The power of a decentralized network like the
SOPHiA DDM™ Platform is that diverse data inputs are continuously
added to the network to fuel and teach our artificial intelligence
algorithms, helping to produce stronger data outputs each time,"
said Jurgi Camblong, PhD., CEO and Co-founder, SOPHiA GENETICS.
"The diverse data that will be unlocked through the partnership
between SOPHiA GENETICS, AstraZeneca, and MSK will undoubtedly
contribute to the collective intelligence needed on a global scale
to revolutionize the future of cancer research and treatment."
"MSK is excited to collaborate with SOPHiA GENETICS and
AstraZeneca to bring our advanced genomic testing to new
populations," said Anaeze Offodile II, MD, MPH, Chief Strategy
Officer, MSK. "We believe that this collaboration will enable
patients from around the world to better understand the genomic
profile of their cancer. Expanding this to a global population
generates a more diverse data set to help develop treatments that
could benefit different and often underserved populations."
This collaboration aims to generate an unparalleled and
comprehensive dataset sourced from diverse populations to provide
invaluable insights and knowledge that could shape the future of
global healthcare.
"While cancer continues to be a leading cause of death
worldwide, we know that a key barrier for cancer patients and their
physicians is a lack of access to high-quality comprehensive
genomic testing. Broad access to quality testing can vastly improve
cancer diagnosis and physicians' treatment decisions," said
Kristina Rodnikova, Head of Global Oncology Diagnostics,
AstraZeneca. "We believe that our collaboration with MSK and SOPHiA
GENETICS will provide physicians and patients with the reliable
data that they need to better diagnose their disease."
The first iterations of this program are expected to be
available for healthcare institutions before the end of 2023.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X (formerly known
as Twitter), LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X (formerly known
as Twitter), LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
About Memorial Sloan Kettering Cancer Center
The
people of Memorial Sloan Kettering Cancer Center (MSK) are united
by a singular mission: ending cancer for life. Our specialized care
teams provide personalized, compassionate, expert care to patients
of all ages. Informed by basic research done at our Sloan Kettering
Institute, scientists across MSK collaborate to conduct innovative
translational and clinical research that is driving a revolution in
our understanding of cancer as a disease and improving the ability
to prevent, diagnose, and treat it. MSK is dedicated to training
the next generation of scientists and clinicians, who go on to
pursue our mission at MSK and around the globe. One of the world's
most respected comprehensive centers devoted exclusively to cancer,
we have been recognized as one of the top two cancer hospitals in
the country by U.S. News & World Report for more than 30 years.
www.mskcc.org
Memorial Sloan Kettering
(MSK) has institutional financial interests related to SOPHiA
GENETICS.
1
https://www.cancer.org/about-us/our-global-health-work/global-cancer-burden.html#:~:text=Cancer%20is%20the%20second%20leading,%2Dmiddle%2Dincome%20countries1.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-enters-new-collaboration-with-memorial-sloan-kettering-cancer-center-and-astrazeneca-to-address-global-inequalities-in-comprehensive-cancer-care-301959953.html
SOURCE SOPHiA GENETICS